How Have Applied DNA Sciences Inc. (APDN) Insiders Been Trading?


Applied DNA Sciences Inc. (NASDAQ:APDN) finished Friday with an addition of $0.4 to close at $1.66, an upside of 31.75 percent. An average of 241,260 shares of common stock have been traded in the last five days. There was a gain of $0.3500 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 146,060 shares traded, while the 50-day average volume stands at 210,032.

APDN stock has increased by 22.06% in the last month. The company shares reached their 1-month lowest point of $1.2000 on 12/21/22. With the stock rallying to its 52-week high on 08/04/22, shares of the company touched a low of $0.62 and a high of $7.35 in 52 weeks. It has reached a new high 3 times so far this year and lost -58.71% or -$2.3600 in price. In spite of this, the price is down -77.41% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

Applied DNA Sciences Inc. (APDN) stock’s beta is 0.62. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.18, the price-to-book (PB) ratio at 1.46.

Financial Health

The quick ratio of Applied DNA Sciences Inc. for the three months ended June 29 was 4.60, and the current ratio was 4.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $5.05 million compared to revenue of $18.17 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Applied DNA Sciences Inc.’s return on assets was -56.40%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$0.66 million in the quarter, while revenues of -$1.12 million were shrunk -583.33%. The analyst consensus anticipated Applied DNA Sciences Inc.’s latest quarter earnings to come in at -$0.35 per share, but it turned out to be -$0.13, a 62.90% surprise. For the quarter, EBITDA amounted to -$4.18 million. At the end of the quarter ending June 29, Applied DNA Sciences Inc.’s stock balance sheet showed total liabilities of 9.36 million. Shareholders own equity worth $12.91 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Applied DNA Sciences Inc. (APDN) price momentum. RSI 9-day as of the close on 30 December was 71.03%, suggesting the stock is Overbought, with historical volatility in this time frame at 153.54%.

As of today, APDN’s price is $1.3620 +26.72% or $0.3500 from its 5-day moving average. APDN is currently trading +1.22% higher than its 20-day SMA and -66.60% lower than its 100-day SMA. However, the stock’s current price level is -9.78% below the SMA50 and -20.57% below the SMA200.

The stochastic %K and %D were 47.29% and 31.85%, respectively, and the average true range (ATR) was 0.1194. With the 14-day stochastic at 98.06% and the average true range at 0.1230, the RSI (14) stands at 61.69%. The stock has reached 0.0856 on the 9-day MACD Oscillator while the 14-day reading was at 0.0495.

Analyst Ratings

ROTH Capital launched coverage on Applied DNA Sciences Inc. (NASDAQ: APDN) in its analyst report released on February 12, 2021. The firm assigned the stock a Buy rating. The consensus rating for Applied DNA Sciences Inc. (APDN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell APDN, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.

What is APDN’s price target for the next 12 months?

Analysts predict a range of price targets between $3.00 and $5.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for Applied DNA Sciences Inc. (APDN) stock is $4.00.


Please enter your comment!
Please enter your name here